Summary: 64Cu-TETA-Octreotide as a PET Imaging Agent
for Patients with Neuroendocrine Tumors
Carolyn J. Anderson, Farrokh Dehdashti, P. Duffy Cutler, Sally W. Schwarz, Richard Laforest, Laura A. Bass,
Jason S. Lewis, and Deborah W. McCarthy
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
64Cu (half-life, 12.7 h; , 0.653 MeV [17.4%]; , 0.579 MeV
[39%]) has shown potential as a radioisotope for PET imaging
and radiotherapy. 111In-diethylenetriaminepentaacetic acid
(DTPA)-D-Phe1-octreotide (OC) was developed for imaging so-
matostatin-receptor­positive tumors using conventional scin-
tigraphy. With the advantages of PET over conventional scin-
tigraphy, an agent for PET imaging of these tumors is desirable.
Here, we show that 64Cu-TETA-OC (where TETA is 1,4,8,11-
tetraazacyclotetradecane-N,N ,N ,N -tetraacetic acid) and
PET can be used to detect somatostatin-receptor­positive tu-
mors in humans. Methods: Eight patients with a history of
neuroendocrine tumors (five patients with carcinoid tumors and
three patients with islet cell tumors) were imaged by conven-
tional scintigraphy with 111In-DTPA-OC (204­233 MBq [5.5­6.3
mCi]) and by PET imaging with 64Cu-TETA-OC (111 MBq [3

Source: Anderson, Carolyn J. - Department of Molecular Biology and Pharmacology, Washington University in St. Louis

Collections: Biology and Medicine